semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 20.0-70.0,  Hepatitis C, Chronic Chronic hepatitis C, diagnosed by positive anti-hepatitis C virus(HCV) antibodies and detected HCV ribonucleic acid(RNA) at screening in addition to: 1. positive anti-HCV antibodies or detected HCV RNA at least 6 months prior to screening; or, 2. liver biopsy consistent with chronic HCV infection HCV infection of genotype 1 confirmed by genotypic testing at screening Therapy-naïve to interferon, pegylated interferon, ribavirin or any antiviral / immunomodulatory drug for acute or chronic HCV infection Plasma HCV RNA = 100,000 IU/mL at screening  Hepatitis C infection of mixed genotype (1/2, 1/3, and 1/4) diagnosed by genotypic testing at screening Human immunodeficiency virus (HIV) co-infection Decompensated liver disease, or history of decompensated liver disease Body weight < 40 or > 125 kg at screening Hemoglobin <12.0g/dL for women and <13.0g/dL for men at screening White blood cell count <3000 cells/mm3 at screening Absolute neutrophil count < 1,500 cells/mm3 at screening Platelet count < 90,000 /mm3 at screening Serum creatinine > 1.5xUpper Limit of Normal range(ULN) or creatinine clearance =50 mL/min at screening
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Hepatitis C has a Body Mass Index (BMI) ≥18.5 kg/m² and ≤36.0 kg/m² has chronic compensated, genotype 1 HCV infection has no cirrhosis of the liver as confirmed by FibroSure®/Fibro Test® and/or local country procedure (e.g. transient elastography/Fibroscan) does not require anticoagulants, nonsteroidal anti-inflammatory agents, and aspirin for at least fourteen (14) days preceding the initial liver biopsy and continuing throughout the entire study if is a female participant of reproductive potential, is willing to use 2 medically acceptable forms of contraception for 2 weeks prior to start of treatment through 2 weeks after last study treatment if is a male participant with a partner(s) of reproductive potential, is willing to use 2 medically acceptable forms of contraception from first dose to 90 days after last dose  has a history of stroke, chronic seizures, or major neurological disorder has received previous treatment with a direct-acting antiviral (DAA) has evidence of high grade bridging fibrosis from prior liver biopsy within 3 years of study entry has evidence or history of chronic hepatitis not caused by HCV infection including but not limited to non-HCV viral hepatitis, nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, or autoimmune hepatitis has clinical or laboratory evidence of cirrhosis or other advanced liver disease has decompensated liver disease as indicated by a history of ascites, hepatic encephalopathy, or bleeding esophageal varices has been diagnosed with, or suspected of having, hepatocellular carcinoma (HCC) has clinically significant abnormality on an electrocardiogram (ECG) is co-infected with human immunodeficiency virus (HIV) is positive for Hepatitis B surface antigen (HBsAg) or other evidence of active Hepatitis B infection
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatitis C, Chronic Is ≥ 40 kg and ≤ 125 kg Documented CHC genotype 1 with HCV RNA ≥10,000 International Units (IU)/mL Has IL-28B CC allele gene Has had a liver biopsy without evidence of cirrhosis and hepatocellular carcinoma (non-invasive fibroscan and Fibrotest can also be used for staging of liver disease)  Co-infection with the human immunodeficiency virus (HIV) or hepatitis B virus (Hepatitis B surface antigen [HBsAg] or HIV positive) Previously treated with an interferon and ribavirin regimen or HCV direct acting antiviral regimen Treatment for hepatitis C with any investigational medication, or prior treatments with herbal remedies with known hepatotoxicity Receiving any medication(s) within 2 weeks prior to the Day 1 visit that are highly dependent on Cytochrome P450 3A4 (CYP3A4/5) for clearance, and for which elevated plasma concentrations could be associated with serious and/or life-threatening events Participation in any other clinical trial within 30 days of the screening visit in this trial or intention to participate in another clinical trial during participation in this trial Evidence of decompensated liver disease or hepatocellular carcinoma (HCC) Is diabetic and/or hypertensive with significant retinopathy Has any known medical condition that could interfere with the participation in and completion of the trial including immunologically-mediated disease, chronic pulmonary disease, or current or history of any clinically significant cardiac abnormalities/dysfunction Evidence of active or suspected malignancy, or a history of malignancy, within the last 5 years Hemoglobin <12 g/dL for females and <13 g/dL for males
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Liver Disease Male or female patients at least 18 years of age. 2. Patients with liver disease. 3. Patients who have need for plasma therapy for a surgical or an invasive procedure or who have evidence of bleeding. 4. Patients with an elevated international normalized ratio due to liver disease. 5. Patients who have given written informed consent or for whom written informed consent has been obtained from the patient's legal representative on their behalf. 6. Patients able and willing to comply with the procedures laid out in the study protocol  Patients who are clinically unstable. 2. Patients who have received mediations that could interfere with results of laboratory testing. 3. Patients who have congenital or acquired coagulopathies of non-hepatic origin. 4. Pregnant or nursing women. 5. Active illicit drug use. 6. Patients participating in another clinical treatment study currently or during the past 1 month prior to study inclusion. 7. Patients previously enrolled in this study
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Chronic Hepatitis C Infection Male or female between the age of 18 and 70 years, inclusive, at time of enrollment Subject has never received antiviral treatment for hepatitis C virus (HCV) infection Body mass index (BMI) is ≥ 18 to < 38 kg/m^2. BMI is calculated as weight measured in kilograms (kg) divided by the square of height measured in meters (m) Chronic HCV genotype 1-infection for at least 6 months prior to study enrollment Subject has plasma HCV RNA level > 10,000 IU/mL at screening  History of severe, life-threatening or other significant sensitivity to any drug Females who are or plan to become pregnant or breastfeeding or males whose partner is pregnant or planning to become pregnant Recent history of drug or alcohol abuse that could preclude adherence to the protocol Positive test result for hepatitis B surface antigen or anti-human immunodeficiency virus (HIV) antibodies Any current or past clinical evidence of cirrhosis (e.g., ascites, esophageal varices), or a liver biopsy or FibroTest/aspartate aminotransferase to platelet ratio (APRI) or FibroScan® showing cirrhosis or extensive bridging fibrosis
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Hepatitis C Genotype 4 Hepatitis C virus (HCV) infection (confirmed at screening) Plasma HCV ribonucleic acid (RNA) of >10,000 IU/mL at screening Participants should be either treatment-naïve or treatment-experienced (non-responder or relapser) with adequate documentation of previous response Participants must have voluntarily signed an Informed Consent Form (ICF) indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. To participate in the optional pharmacogenomic component in this study (exploratory host genotyping), participants must have voluntarily signed a separate ICF for this component (where local regulations permit). Refusal to give consent for this component does not a participant from participation in the core study Participants must have had a liver biopsy within 3 years prior to screening (or between screening and baseline visit) with histology consistent with chronic HCV infection  Has an infection/co-infection with non-genotype 4 HCV Has a co-infection with Human Immunodeficiency Virus (HIV) type 1 or type 2 (HIV-1 or HIV-2) (positive HIV-1 or HIV-2 antibodies test at screening) Has any of the following laboratory abnormalities: 1. Platelet count <90,000/mm3; 2. Absolute neutrophil count (ANC) <1500 cells/mm3 (Blacks: <1200 cells/mm3); 3. Hemoglobin <12 g/dL for women and <13 g/dL for men; 4. Creatinine >1.5 mg/dL; 5. ALT and/or AST >10 x upper limit of normal (ULN); 6. Total serum bilirubin >1.5 x ULN; 7. Alpha-fetoprotein [AFP] >50 ng/mL; 8. Albumin plasma concentration <3.5 g/dL; 9. Prothrombin time (PT) expressed as international normalized ratio (INR) >1.5. Note: retesting of abnormal laboratory values that leads to will be allowed once using an unscheduled visit during the screening period to assess eligibility Used disallowed concomitant therapy Has evidence of hepatic decompensation (history or current evidence of ascites, bleeding varices or hepatic encephalopathy)
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 0.0-85.0,  Idiopathic Normal Pressure Hydrocephalus At least two out of three of the typical signs of normal pressure hydrocephalus gait disturbance cognitive impairment and urinary incontinence Radiological verification of a communicating hydrocephalus Cerebrospinal fluid pressure at lumbar puncture < 150 mm H2O  Aqueduct stenosis Severe comorbidity Age > 85 years Possibly confounding neurological diseases Recent meningitis or subarachnoid hemorrhage
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hepatitis C Virus For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Chronic hepatitis C genotype 1. GT-1b Capped at 50 % of naïve subjects Naives to prior anti-HCV therapy [Interferon (IFN) and direct antiviral agent (DAA) based] Relapsers (defined as subjects who had undetectable HCV ribonucleic acid (RNA) on prior treatment regimen of alfa-2a/RBV and Hepatitis C Virus (HCV) RNA > 25IU/mL after discontinuation of treatment). Capped at 20% HCV RNA ≥ 100,000 IU/mL Subjects with compensated cirrhosis can be enrolled and will be capped at approximately 10% Seronegative for human immunodeficiency virus (HIV) and hepatitis B surface antigen (HBsAg) Men or women, 18-70 years of age  Chronic liver disease due to causes other than chronic HCV Current or past evidence of decompensation Conditions that preclude the use of Alfa/RBV/TVR per respective labels Diagnosed or suspected hepatocellular carcinoma
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Hepatitis C Infection with HCV Must have participated in a prior Gilead HCV study Use of highly effective contraception methods if female of childbearing potential or sexually active male Eligible patients those in the following received placebo or Peg-IFN+RBV in a control arm previously participated in a Gilead-sponsored HCV study and did not attain sustained virologic response 24 weeks after discontinuation of therapy (SVR24) on a regimen containing Sofosbuvir+RBV Peg-IFN and/or RBV in combination with one or more Gilead investigational direct-acting agents  Pregnant or nursing female or male with pregnant female partner Current or prior history of clinical hepatic decompensation Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) Chronic use of systemically administered immunosuppressive agents Active drug abuse Use of any prohibited concomitant medications
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 0.083-999.0,  Non-Alcoholic Steato-Hepatitis Liver Cirrhosis Non-Alcoholic Fatty Liver Disease Although a liver biopsy is necessary to make the diagnosis of NASH, patients with radiologic evidence of fatty liver and/or cirrhosis in which other causes have been ruled out are eligible to participate. 2. Patients who have already undergone liver transplantation for a confirmed diagnosis of NAFLD or cryptogenic cirrhosis are also eligible to participate. 3. Depending on their willingness to participate, subjects may enroll in DNA laboratory-only or clinical-only. However, to conserve resources and meet study objectives, subjects with known pathogenic mutations will be given priority in selection for extensive clinical studies. 4. Direct blood relatives (typically parents and siblings) of affected individuals with NAFLD and associated conditions are also eligible to participate  Anyone unwilling to provide informed consent (for themselves as adults, or on behalf of their children as minors) or assent. 2. Pregnant women. Although fatty liver and cirrhosis are sometimes diagnosed during pregnancy, it is unclear if they were present before and just not diagnosed or if they develop as a complication of pregnancy. Additionally energy metabolism changes during pregnancy and lactation which may confound our analysis. If the condition persists after pregnancy and the diagnosis of NAFLD is clearly established, patients can be referred to the study. 3. We will review a clinical description from the referring physician about a potential research subject to determine that the subject is appropriate to enter into the study. We reserve the right to cases that are clearly not NAFLD or related to our direct research interests (e.g. fatty liver induced by chronic alcohol use, infectious causes, drug-related, or toxin-related). This almost never happens. However, as some of these environmental factors may contribute to a multifactorial etiology of hepatic changes, we may not all such cases